Animal studies [75,77,79,80] have revealed that elevated hepatic de novo lipogenesis contributes significantly to MASLD, and inhibition of ATP-citrate lyase (ACLY), a key enzyme in lipogenesis, has been shown to effectively control hepatic steatosis. Here, ACLY is linked to fatty liver disease.